CSIMarket
 
Nkarta Inc   (NKTX)
Other Ticker:  
 

Nkarta Inc

Officers & Directors


1. Paul Hastings (President and CEO)
2. Brian Kotzin (Chief Medical Officer)
3. Jared Weiss (Chief Financial Officer)
4. Christina Tartaglia (Chief Operating Officer)
5. Daniel Kaufman (Chief Scientific Officer)

Board of Directors:
1. Arthur Tzianabos (Chairman of the Board)
2. Avik Roy
3. Peter Moldt
4. Robert Booth
5. Sean Parker
6



  News about Nkarta Inc Key Personnel

Nkarta's Underwritten Offering Amidst Financial Struggles Sparks Debate Over Future Growth Potential in Biopharmaceutical Sector

Nkarta's Recent Underwritten Offering and Financial Performance Reflects Volatility in Biopharmaceutical Sector
SOUTH SAN FRANCISCO, Calif., March 25, 2024 - Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company specializing in the development of engineered natural killer (NK) cell therapies, recently announced the pricing of an underwritten offering, aiming to raise $240 million. However, this news comes amid concerns regarding the company's financial performance, particularly with a cumulative net loss of $122 million recorded during the 12 months ending in the third quarter of 2023. This indicates a negative return on investment (ROI) of -29.38%, highlighting potential challenges for investors.





NKTX Management Effectiveness NKTX Revenue per Employee NKTX Income per Employee


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com